Objective
The Constitutive morphogenetic protein 1 (Cop1) is an E3-ubiquitin ligase regulating stability of a broad group of targets with pleiotropic functions. Cop1 emerged as a tumour suppressor in T-cell lymphomas and in prostate cancer. During tumour formation, mitochondria are key organelles regulating cell death and proliferation. This multiplicity of functions is mirrored by the complex morphology of the organelle, resulting from the equilibrium between fusion and fission, events controlled by a set of mitochondria-shaping proteins. Fission depends on the large GTPase dynamin-related protein 1 (DRP1), essential for embryonic development and involved in the control of apoptosis and cell cycle.We found that loss of Cop1 results in increased cell death, DNA damage, mitochondrial fragmentation, and accumulation of D1, highlighting a potential connection between a tumour suppressor and mitochondrial morphology. We therefore hypothesize that Drp1-mediated regulation of mitochondrial morphology participates in tumour suppression by Cop1. To address this hypothesis, we will verify if (i) Drp1 is epistatic to Cop1 in accumulation of DNA damage and sensitivity to cell death; (ii) Drp1 is required for lymphomagenesis in Cop1h/h mice . Our project is expected to establish the role of mitochondrial morphology in Cop1 regulated tumour development.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology prostate cancer
- natural sciences biological sciences genetics DNA
- natural sciences biological sciences biochemistry biomolecules proteins
- natural sciences biological sciences developmental biology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2011-IEF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
1211 Geneve
Switzerland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.